Skip to main content

Hydrogel/Polymersome-based Subunit Vaccines in the Fight Against COVID-19

Project description

Enlisting supramolecular hydrogels to fight coronavirus

Most vaccines in use today were developed using techniques invented more than 100 years ago. The design of vaccines that have ease of distribution and reduced cost remains a major technological challenge. In view of the COVID-19 pandemic, there is growing pressure to develop new technologies to address severe infectious diseases. The EU-funded HYPOVACC project will develop a novel biocompatible, injectable and scalable vaccine technology based on supramolecular hydrogel-containing polymersomes to enable controlled local vaccine exposure for durable and broadly protective immune response against the coronavirus. The project research will cover new vaccine delivery technologies and recently developed immunological assays.

Call for proposal

H2020-MSCA-IF-2020
See other projects for this call

Coordinator

UNIVERSITE DE BORDEAUX
Address
Place Pey Berland 35
33000 Bordeaux
France
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 257 619,84

Partners (1)

BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
United States
Address
Serra Mall 450
94305 2004 Stanford
Activity type
Higher or Secondary Education Establishments